The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
Transcript (slightly modified for readability)
What is the objective of the Community Oncology Alliance's Payer Exchange Summit?
So at COA we had this dream over a year ago of getting providers and payers together at a summit. In fact, we called it the Payer Exchange Summit on Oncology Payment Reform. We wanted to get provider and payer teams that were actually working on oncology payment reform to talk about "what are we doing? What's working? What's not working?"
So now that we've done the first summit a year ago, we did the second summit when we devoted half a day at our conference in April, and now that we've just finished the third summit, we're really seeing a great opportunity here to get more payers involved in the dialogue. Not just the really progressive payers that are actually doing things in oncology payment reform, like Aetna, like UnitedHealthcare, but literally to get payers that are thinking about doing something or want to know what they should be doing to literally have them exposed to pilots that are working now with actual payers and providers.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More